The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Open accessAbstract
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths. RESULTS: At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects. CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vemurafenib, a selective oral inhibitor of the BRAF V600 kinase, achieved an approximately 50% response and improved survival among metastatic melanoma patients with the BRAF V600E mutation [97].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [97]
In the citing paper
“Maturation of survival data also increased the ESMO-MCBS score of vemurafenib in the treatment of metastatic melanoma [116, 117] from ESMO-MCBS 3 based on PFS to 4, based on OS.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Research works printed but not linked: 1
- Kumar R, 2003, Clin Cancer Res, 9, 3362
Cited by
Sorted by citations
Items 401–500 of 1,053
Hong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219
Gajjar, A. J., Bowers, D. C., Karajannis, M. A., Leary, S. E. S., Witt, H., & Gottardo, N. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.9217 · Cited by 222
From target discovery to clinical drug development with human genetics
Trajanoska, K., Bhérer, C., Taliun, D., Zhou, S., Richards, J. B., & Mooser, V. (2023) · Nature · doi:10.1038/s41586-023-06388-8 · Cited by 229
“This approach has been successful for CFTR modulators in cystic fibrosis 136 and cancer drugs 137 .”
MethodSahm, F., Capper, D., Preusser, M., Meyer, J., Stenzinger, A., Lasitschka, F., Berghoff, A. S., Habel, A., Schneider, M., Kulozik, A. E., et al. (2012) · Blood · doi:10.1182/blood-2012-06-429597 · Cited by 220
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
Flaherty, K. T., Lee, S. J., Zhao, F., Schuchter, L. M., Flaherty, L. E., Kefford, R. F., Atkins, M. B., Leming, P. D., & Kirkwood, J. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1529 · Cited by 220
Self-citation3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets
Gao, J., Chang, M. T., Johnsen, H. C., Gao, S. P., Sylvester, B. E., Sümer, S. O., Zhang, H., Solit, D. B., Taylor, B. S., Schultz, N. D., et al. (2017) · Genome Medicine · doi:10.1186/s13073-016-0393-x · Cited by 220
The mutational landscape of mucosal melanoma
Nassar, K. W., & Tan, A. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.013 · Cited by 227
Molecular Markers and Targets in Melanoma
Teixidó, C., Castillo, P., Martínez-Vila, C., Arance, A. M., & Alós, L. (2021) · Cells · doi:10.3390/cells10092320 · Cited by 262
“ipilimumab in 2011, the first immune checkpoint inhibitor (ICI) to improve survival in the advanced setting [7,8], and vemurafenib, a v-raf murine sarcoma viral oncogene homolog B1 (BRAF) tyrosine kinase inhibitor, first in class [9,10].”
BackgroundDrug resistance to targeted therapeutic strategies in non-small cell lung cancer
Liu, W., Du, Y., Wen, R. M., Yang, M., & Xu, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107438 · Cited by 223
Atg7 Overcomes Senescence and Promotes Growth of Braf V600E-Driven Melanoma
Xie, X., Koh, J. Y., Price, S., White, E., & Mehnert, J. M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1473 · Cited by 208
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216
Self-citationPhenformin enhances the therapeutic benefit of BRAF V600E inhibition in melanoma
Yuan, P., Ito, K., Pérez‐Lorenzo, R., Guzzo, C. D., Lee, J. H., Shen, C., Bosenberg, M., McMahon, M., Cantley, L. C., & Zheng, B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317577110 · Cited by 226
Therapy for metastatic melanoma: the past, present, and future
Finn, L. E., Markovic, S. N., & Joseph, R. W. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-23 · Cited by 224
Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
Lacouture, M. E., Duvic, M. A., Hauschild, A., Prieto, V. G., Robert, C., Schadendorf, D., Kim, C. C., McCormack, C. J., Myskowski, P. L., Spleiss, O., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0333 · Cited by 217
Self-citationCancer Neoantigens and Applications for Immunotherapy
Desrichard, A., Snyder, A., & Chan, T. A.-T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3175 · Cited by 219
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh, S. J., Rizos, H., Scolyer, R. A., & Long, G. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.005 · Cited by 224
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 215
Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P. A., Herbert, C., Mackiewicz, A. A., Rutkowski, P., Guminski, A. D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30106-2 · Cited by 215
Self-citationJohnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L. M., Cebon, J. S., Sharfman, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3535 · Cited by 219
Self-citationKim, G., McKee, A. E., Ning, Y. M., Hazarika, M., Theoret, M. R., Johnson, J. R., Xu, Q. C., Tang, S., Sridhara, R., Jiang, X., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0776 · Cited by 219
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019
Garbe, C., Amaral, T. M. S., Peris, K., Hauschild, A., Arenberger, P., Bastholt, L., Bataille, V. A., del Mármol, V., Dréno, B., Fargnoli, M. C., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.015 · Cited by 218
“The longest established monotherapy is DTIC.”
BackgroundInfluentialSelf-citationCapper, D., Berghoff, A. S., Magerle, M., İlhan, A., Wöehrer, A., Hackl, M., Pichler, J., Pusch, S., Meyer, J., Habel, A., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0887-y · Cited by 212
Hou, S., Zhao, L., Shen, Q., Yu, J., Ng, C., Kong, X., Wu, D., Song, M., Shi, X., Xu, X., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208452 · Cited by 212
Self-citationGirotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.006 · Cited by 212
Self-citationMolecular pathogenesis, targeted therapies, and future perspectives for gastric cancer
Zeng, Y., & Jin, R. U. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.12.004 · Cited by 221
Tsimberidou, A. M., Wen, S., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S. A., Naing, A., Jankú, F., Aldape, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0603 · Cited by 210
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 221
Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells
Baldari, S., Rocco, G. D., Heffern, M. C., Su, T. A., Chang, C. J., & Toietta, G. (2019) · Cancers · doi:10.3390/cancers11050659 · Cited by 211
“Inhibition of the BRAF oncoprotein by vemurafenib has been shown to be highly effective in BRAFV600E melanoma patients [22]; in contrast, the same treatment has limited effect on BRAFV600E colon cancer patients due to intrinsic resistance against BRAF inhibitors [6,23].”
BackgroundDrug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 222
Luna, A., Elloumi, F., Varma, S., Wang, Y., Rajapakse, V. N., Aladjem, M. I., Robert, J., Sander, C., Pommier, Y. G., & Reinhold, W. C. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa968 · Cited by 212
“9e−15), primarily in the melanoma cell lines, as expected due to their large presence of the V600E mutations (75,76).”
BackgroundCancer gene mutation frequencies for the U.S. population
Mendiratta, G., Ke, E., Aziz, M., Liarakos, D., Tong, M. M., & Stites, E. C. (2021) · Nature Communications · doi:10.1038/s41467-021-26213-y · Cited by 225
Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma
Vardabasso, C., Gaspar‐Maia, A., Hasson, D., Pünzeler, S., Valle‐García, D., Straub, T., Keilhauer, E. C., Strub, T., Dong, J., Panda, T., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.009 · Cited by 214
Young, R. J., Waldeck, K., Martin, C., Foo, J. H., Cameron, D. P., Kirby, L., Do, H., Mitchell, C., Cullinane, C. M., Liu, W. J., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12228 · Cited by 206
Self-citationCutaneous toxicities of RAF inhibitors
Anforth, R. M., Fernández‐Peñas, P., & Long, G. V. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70413-8 · Cited by 204
The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
Maroun, C. R., & Rowlands, T. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.014 · Cited by 206
Boussemart, L., Routier, É., Mateus, C., Opletalova, K., Sébille, G., Kamsu-Kom, N., Thomas, M., Vagner, S., Fãvre, M., Tomasic, G., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt015 · Cited by 209
Self-citationTovar, V., Cornellà, H., Moeini, A., Vidal, S. J., Hoshida, Y., Sia, D., Peix, J., Cabellos, L., Alsinet, C., Torrecilla, S., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-309501 · Cited by 204
Karoulia, Z., Wu, Y., Ahmed, T. A., Xin, Q., Bollard, J., Krepler, C., Wu, X., Zhang, C., Bollag, G. E., Herlyn, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.024 · Cited by 205
Lovly, C. M., Dahlman, K. B., Fohn, L. E., Su, Z., Dias-Santagata, D. C., Hicks, D. J., Hucks, D., Berry, E., Terry, C. R., Duke, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035309 · Cited by 203
Self-citationKuk, D., Shoushtari, A. N., Barker, C. A., Panageas, K. S., Munhoz, R. R., Momtaz, P., Ariyan, C. E., Brady, M. S., Coit, D. G., Bogatch, K., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0522 · Cited by 204
The rise of the genome and personalised medicine
Brittain, H. K., Scott, R. H., & Thomas, E. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-6-545 · Cited by 204
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208
Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
Tan, D. S. W., Mok, T. S. K., & Rebbeck, T. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0096 · Cited by 206
Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy
Lee, J., Liu, Z., Sa, J. K., Shin, S. H., Wang, J., Bordyuh, M., Cho, H. J., Elliott, O., Chu, T., Choi, S. W., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0209-6 · Cited by 207
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 225
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
McDermott, D. F., Lebbé, C., Hodi, F. S., Maio, M., Weber, J. S., Wolchok, J. D., Thompson, J. A., & Balch, C. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.012 · Cited by 205
Self-citationGopal, Y. N. V., Rizos, H., Chen, G., Deng, W., Frederick, D. T., Cooper, Z. A., Scolyer, R. A., Pupo, G. M., Komurov, K., Sehgal, V., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1392 · Cited by 203
Wiesner, T., Kutzner, H., Cerroni, L., Mihm, M. C., BUSAM, K. J., & Murali, R. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.007 · Cited by 205
Cutaneous Squamous Cell Carcinoma: From Biology to Therapy
Corchado‐Cobos, R., García‐Sancha, N., González‐Sarmiento, R., Pérez‐Losada, J., & Cañueto, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082956 · Cited by 225
Yadav, V., Zhang, X., Liu, J., Estrem, S., Li, S., Gong, X.-Q., Buchanan, S., Henry, J. R., Starling, J. J., & Peng, S.-B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377218 · Cited by 200
Acquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
Brain metastases: pathobiology and emerging targeted therapies
Preusser, M., Capper, D., Ilhan‐Mutlu, A., Berghoff, A. S., Birner, P., Bartsch, R., Marosi, C., Zielinski, C. C., Mehta, M. P., Winkler, F., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0933-9 · Cited by 199
Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
Hu‐Lieskovan, S., Robert, L., Moreno, B. H., & Ribas, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.1377 · Cited by 202
Self-citationBRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Dahlman, K. B., Xia, J., Hutchinson, K. E., Ng, C., Hucks, D., Jia, P., Atefi, M. S., Su, Z., Branch, S., Lyle, P. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0097 · Cited by 196
Self-citationDelord, J., Robert, C., Nyakas, M., McArthur, G. A., Kudchakar, R., Mahipal, A., Yamada, Y., Sullivan, R. J., Arance, A. M., Kefford, R. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2923 · Cited by 203
Self-citationTargeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 199
Yang, J., & Hu, L. (2018) · Medicinal Research Reviews · doi:10.1002/med.21530 · Cited by 201
“106 of 219 patients; two complete responses [CR] and 104 partial responses [PR]) as compared to those in the dacarbazine treatment group (5%; 12 of 220 patients; all PRs).(3) In addition, vemurafenib significantly improved survival when compared to dacarbazine (progression‐free survival [PFS] of 5.”
BackgroundResultRietveld, P., & Bruinsma, F. R. (1998) · Data Archiving and Networked Services (DANS) · Cited by 198
Kim, K. B., Cabanillas, M. E., Lazar, A. J., Williams, M. D., Sanders, D. L., Ilagan, J. L., Nolop, K. B., Lee, R. J., & Sherman, S. I. (2013) · Thyroid · doi:10.1089/thy.2013.0057 · Cited by 201
Self-citationThomas, N. E., Edmiston, S. N., Alexander, A. A., Groben, P. A., Parrish, E., Kricker, A., Armstrong, B. K., Anton‐Culver, H., Gruber, S. B., From, L., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0493 · Cited by 202
Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
Gibney, G. T., Messina, J. L., Smalley, I., Sondak, V. K., & Smalley, K. S. M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.83 · Cited by 199
Kaufman, H. L., Kirkwood, J. M., Hodi, F. S., Agarwala, S. S., AMATRUDA, T. T., Bines, S. D., Clark, J. I., Curti, B. D., Ernstoff, M. S., Gajewski, T. F., et al. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.153 · Cited by 199
Self-citationNathanson, K. L., Martin, A., Wubbenhorst, B. S., Greshock, J. D., Letrero, R., D'Andrea, K. P., O'Day, S. J., Infante, J. R., Falchook, G. S., Arkenau, H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0827 · Cited by 200
Self-citationMolecular Tumor Board: The University of California San Diego Moores Cancer Center Experience
Schwaederle, M. C., Parker, B. A., Schwab, R. B., Fanta, P. T., Boles, S. G., Daniels, G. A., Bazhenova, L. A., Subramanian, R., Coutinho, A., Ojeda‐Fournier, H., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0405 · Cited by 196
Precision Oncology: The Road Ahead
Senft, D., Leiserson, M. D. M., Ruppin, E., & Ronai, Z. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.003 · Cited by 199
Management of conjunctival malignant melanoma: a review and update
Wong, J. R., Nanji, A., Galor, A., & Karp, C. L. (2014) · Expert Review of Ophthalmology · doi:10.1586/17469899.2014.921119 · Cited by 198
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., Mao, X., De Macedo, M. P., Chen, J., Song, X., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0013-8 · Cited by 166
Tumor Evolution as a Therapeutic Target
Amirouchene-Angelozzi, N., Swanton, C., & Bardelli, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0343 · Cited by 197
Chowdhury, P. S., Chamoto, K., & Honjo, T. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12708 · Cited by 198
Therapeutic implications of menin inhibition in acute leukemias
Issa, G. C., Ravandi, F., Dinardo, C. D., Jabbour, E. J., Kantarjian, H. M., & Andreeff, M. (2021) · Leukemia · doi:10.1038/s41375-021-01309-y · Cited by 200
van der Meer, D., Barthorpe, S., Yang, W., Lightfoot, H., Hall, C., Gilbert, J., Francies, H. E., & Garnett, M. J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky872 · Cited by 195
“…of anti-cancer drugs, such as the epidermal growth factor receptor (EGFR) inhibitor gefitinib for the treatment of non-small-cell lung cancer (1), inhibitors of the protein kinase BRAF in melanoma (2) and anaplastic lymphoma kinase (ALK) inhibitors for ALK-fusion positive lung cancer (3).”
BackgroundCirenajwis, H., Ekedahl, H., Lauss, M., Harbst, K., Carneiro, A., Enoksson, J., Rosengren, F., Hartman, L. W., Törngren, T., Kvist, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3655 · Cited by 201
Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer
Coward, J. I. G., & Harding, A. S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00123 · Cited by 197
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
Warner, A. B., Nipp, R. D., Giobbie‐Hurder, A., Johnpulle, R. A. N., Rubin, K. M., Rubinstein, S. M., Flaherty, K. T., Lawrence, D. P., Johnson, D. B., & Sullivan, R. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0450 · Cited by 194
Self-citationMolecular Profiling for Breast Cancer: A Comprehensive Review
Kittaneh, M., Montero, A. J., & Glück, S. (2013) · Biomarkers in Cancer · doi:10.4137/bic.s9455 · Cited by 202
Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
Mangat, P. K., Halabi, S., Bruinooge, S. S., Garrett-Mayer, E. S., Alva, A. S., Janeway, K. A., Stella, P. J., Voest, E. E., Yost, K. J., Perlmutter, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00122 · Cited by 199
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 212
Prognostic and Predictive Biomarkers: Tools in Personalized Oncology
Nalejska, E., Mączyńska, E., & Lewandowska, M. A. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0077-9 · Cited by 202
Hall, A., Meyle, K. D., Lange, M. K., Klima, M., Sanderhoff, M., Dahl, C., Abildgaard, C., Thorup, K., Moghimi, S. M., Jensen, P. B., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.965 · Cited by 191
The Role of PGC1α in Cancer Metabolism and its Therapeutic Implications
Tan, Z., Luo, X., Xiao, L., Tang, M., Bode, A. M., Dong, Z., & Cao, Y. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0621 · Cited by 198
Sabnis, A. J., & Bivona, T. G. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.009 · Cited by 187
Interferon alpha for the adjuvant treatment of cutaneous melanoma
D, S. M. M., Lens, M. B., Pasquali, S., Pilati, P., & Chiarion‐Sileni, V. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008955.pub2 · Cited by 188
Cancer Genomics: Technology, Discovery, and Translation
Tran, B., Dancey, J. E., Kamel‐Reid, S., McPherson, J. D., Bedard, P. L., Brown, A. M. K., Zhang, T., Shaw, P. H., Onetto-Pothier, N., Stein, L. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2316 · Cited by 188
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
Tan, L., Sandhu, S. K., Lee, R. J., Li, J., Callahan, J., Ftouni, S., Dhomen, N. S., Middlehurst, P., Wallace, A. J., Raleigh, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz048 · Cited by 196
Self-citationTargeting the ERK Signaling Pathway in Melanoma
Savoia, P., Fava, P., Casoni, F., & Cremona, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061483 · Cited by 195
“In the phase-III, double-blind SUMIT trial (NCT01974752), 152 patients affected by metastatic uveal melanoma but naive from prior systemic therapies, were randomly assigned (3:1) to selumetinib (75 mg twice daily) plus DTIC (1000 mg/m2 intravenously on day 1 of every 21-day cycle) or placebo plus DTIC [223].”
BackgroundMethodInfluentialNarasimhan, V., Wright, J. A., Churchill, M., Wang, T., Rosati, R., Lannagan, T. R. M., Vrbanac, L., Richardson, A. B., Kobayashi, H., Price, T. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0073 · Cited by 201
New drugs in melanoma: It’s a whole new world
Eggermont, A. M. M., & Robert, C. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.052 · Cited by 185
Self-citationFOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
Loupakis, F., Cremolini, C., Salvatore, L., Masi, G., Sensi, E., Schirripa, M., Michelucci, A., Pfanner, E., Brunetti, I. M., Lupi, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.024 · Cited by 187
Targeting pan-essential genes in cancer: Challenges and opportunities
Chang, L., Ruiz, P. A., Ito, T., & Sellers, W. R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.008 · Cited by 188
BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers
Castellani, G., Buccarelli, M., Arasi, M. B., Rossi, S., Pisanu, M. E., Bellenghi, M., Lintas, C., & Tabolacci, C. (2023) · Cancers · doi:10.3390/cancers15164026 · Cited by 210
“In 2011, the efficacy of vemura enib as a monotherapy comp red to dacarbazine hemoth rapy showed a relative reduction of 63% in the risk of death and of 74% i the risk of tumour progression [81] and the median OS was 13.”
BackgroundTargeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Gautschi, O. P., Milia, J., Cabarrou, B., Bluthgen, M. V., Besse, B., Smit, E. F., Wolf, J., Peters, S., Früh, M., Koeberle, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000625 · Cited by 185
Wilson, M. A., & Schuchter, L. M. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_8 · Cited by 191
Mucosal melanoma of the head and neck
Ascierto, P. A., Accorona, R., Botti, G., Farina, D., Fossati, P., Gatta, G., Gogas, H. J., Lombardi, D., Maroldi, R., Nicolai, P., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.019 · Cited by 188
Self-citationBCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Lee, E. F., Harris, T. J., Tran, S. H., Evangelista, M., Arulananda, S., John, T., Ramnac, C., Hobbs, C., Zhu, H., Gunasingh, G. P., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1568-3 · Cited by 188
Systematic classification of melanoma cells by phenotype‐specific gene expression mapping
Widmer, D. S., Cheng, P. F., Eichhoff, O. M., Belloni, B., Zipser, M. C., Schlegel, N. C., Javelaud, D., Mauviel, A., Dummer, R., & Hoek, K. S. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00986.x · Cited by 195
Self-citationWhole‐exome sequencing of pancreatic neoplasms with acinar differentiation
Jiao, Y., Yonescu, R., Offerhaus, G. J. A., Klimstra, D. S., Maitra, A., Eshleman, J. R., Herman, J. G., Poh, W., Pelosof, L. C., Wolfgang, C. L., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4310 · Cited by 185
Schreuer, M. S., Jansen, Y. J. L., Planken, S., Chevolet, I., Seremet, T., Krüse, V., & Neyns, B. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30171-7 · Cited by 195
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
Du, W., & Elemento, O. (2014) · Oncogene · doi:10.1038/onc.2014.291 · Cited by 185
Thomas, N. E., Kricker, A., Waxweiler, W. T., Dillon, P. M., BUSAM, K. J., From, L., Groben, P. A., Armstrong, B. K., Anton‐Culver, H., Gruber, S. B., et al. (2014) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.1348 · Cited by 183
Metadata
- Authors
- Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O'Day, S. J., Sosman, J. A., Kirkwood, J. M., Eggermont, A. M. M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R. J., Flaherty, K. T., & McArthur, G. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Institut Gustave Roussy (FR)
- The Netherlands Cancer Institute (NL)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Royal Marsden Hospital (GB)
- University of Zurich (CH)
- University of Tübingen (DE)
- European Institute of Oncology (IT)
- Tumour Institute of Tuscany (IT)
- University Health Network (CA)
- University of Manchester (GB)
- Hôpital Saint-André (FR)
- Essen University Hospital (DE)
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- Vanderbilt University (US)
- University of Pittsburgh (US)
- Plexxikon (United States) (US)
- Genentech (US)
- Massachusetts General Hospital (US)
- Peter MacCallum Cancer Centre (AU)
- ORCID
- Chapman, Paul B.
- Hauschild, Axel
- Robert, Caroline
- Haanen, John B.
- Ascierto, Paolo
- Larkin, James
- Dummer, Reinhard
- Garbe, Claus
- Testori, Alessandro
- Maio, Michele
- Hogg, David
- Lorigan, Paul
- Jouary, Thomas
- Schadendorf, Dirk
- Ribas, Antoni
- O'Day, Steven J.
- Sosman, Jeffrey A.
- Kirkwood, John M.
- Eggermont, Alexander M.M.
- Li, Jiang
- Hou, Jeannie
- Lee, Richard J.
- Flaherty, Keith T.
- McArthur, Grant A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-30
- Volume
- 364
- Issue
- 26
- Pages
- 2507-2516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3549296
- OpenAlex
- W2128542677
- Cited by
- 7,720
- References
- 28
- Citations by year
- 2026: 141 · 2025: 187 · 2024: 265 · 2023: 276 · 2022: 401 · 2021: 377 · 2020: 423 · 2019: 470 · 2018: 496 · 2017: 613 · 2016: 660 · 2015: 829 · 2014: 844 · 2013: 865 · 2012: 693
- FWCI
- 332.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institutes of Health (UL1TR000005)
- National Cancer Institute (K24CA097588)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, dacarbazine, metastatic melanoma, BRAF V600E mutation, BRAF inhibitors, overall survival, progression-free survival, drug toxicity, keratoacanthoma, photosensitivity
- MeSH terms
- Vemurafenib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Sulfonamides, Survival Analysis, Disease-Free Survival, Proto-Oncogene Proteins B-raf, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
